 | • レポートコード：QYR2104Z5899 • 出版社/出版日：QYResearch / 2021年4月10日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、133ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、人工呼吸器関連肺炎（VAP）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（予防、理学療法、免疫療法）、用途別市場規模（病院、外来手術センター、診断センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・人工呼吸器関連肺炎（VAP）治療薬の市場動向 ・企業の競争状況、市場シェア ・人工呼吸器関連肺炎（VAP）治療薬の種類別市場規模（予防、理学療法、免疫療法） ・人工呼吸器関連肺炎（VAP）治療薬の用途別市場規模（病院、外来手術センター、診断センター） ・人工呼吸器関連肺炎（VAP）治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・人工呼吸器関連肺炎（VAP）治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・人工呼吸器関連肺炎（VAP）治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・人工呼吸器関連肺炎（VAP）治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・人工呼吸器関連肺炎（VAP）治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Achaogen Inc、Adenium Biotech ApS、Aridis Pharmaceuticals LLC、AstraZeneca Plc、Bayer AG、Cardeas Pharma Corp、Destiny Pharma Ltd、Dong-A Socio Holdings Co Ltd、Lakewood-Amedex Inc、MedImmune LLC、Meiji Seika Pharma Co Ltd、Merck & Co Inc、Motif Bio Plc、Nabriva Therapeutics AG、Polyphor Ltd、Shionogi & Co Ltd、Tetraphase Pharmaceuticals Inc、The Medicines Company、Theravance Biopharma Inc、Wockhardt Ltd、Zavante Therapeutics Inc） ・結論 |
Market Analysis and Insights: Global Ventilator Associated Pneumonia (VAP) Therapeutics Market
The global Ventilator Associated Pneumonia (VAP) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Ventilator Associated Pneumonia (VAP) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Ventilator Associated Pneumonia (VAP) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Ventilator Associated Pneumonia (VAP) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Ventilator Associated Pneumonia (VAP) Therapeutics market.
Global Ventilator Associated Pneumonia (VAP) Therapeutics Scope and Market Size
Ventilator Associated Pneumonia (VAP) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Ventilator Associated Pneumonia (VAP) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Prevention
Physiotherapy
Immunity Therapy
Segment by Application
Hospitals
Ambulatory Surgical Center
Diagnostic Centers
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Achaogen Inc
Adenium Biotech ApS
Aridis Pharmaceuticals LLC
AstraZeneca Plc
Bayer AG
Cardeas Pharma Corp
Destiny Pharma Ltd
Dong-A Socio Holdings Co Ltd
Lakewood-Amedex Inc
AstraZeneca Plc
Bayer AG
Merck & Co Inc
Motif Bio Plc
Nabriva Therapeutics AG
Polyphor Ltd
Shionogi & Co Ltd
Tetraphase Pharmaceuticals Inc
The Medicines Company
Theravance Biopharma Inc
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Prevention
1.2.3 Physiotherapy
1.2.4 Immunity Therapy
1.3 Market by Application
1.3.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Center
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Perspective (2016-2027)
2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Growth Trends by Regions
2.2.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Industry Dynamic
2.3.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Trends
2.3.2 Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers
2.3.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges
2.3.4 Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue
3.1.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue
3.4 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio
3.4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2020
3.5 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players Head office and Area Served
3.6 Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
3.7 Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Type
4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2022-2027)
5 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Application
5.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027)
6.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
6.2.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027)
6.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
6.3.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027)
6.4 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
6.4.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027)
7.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
7.2.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027)
7.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
7.3.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027)
7.4 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
7.4.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027)
9.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
9.2.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
9.3.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
9.4.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Achaogen Inc
11.1.1 Achaogen Inc Company Details
11.1.2 Achaogen Inc Business Overview
11.1.3 Achaogen Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.1.4 Achaogen Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.1.5 Achaogen Inc Recent Development
11.2 Adenium Biotech ApS
11.2.1 Adenium Biotech ApS Company Details
11.2.2 Adenium Biotech ApS Business Overview
11.2.3 Adenium Biotech ApS Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.2.4 Adenium Biotech ApS Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.2.5 Adenium Biotech ApS Recent Development
11.3 Aridis Pharmaceuticals LLC
11.3.1 Aridis Pharmaceuticals LLC Company Details
11.3.2 Aridis Pharmaceuticals LLC Business Overview
11.3.3 Aridis Pharmaceuticals LLC Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.3.4 Aridis Pharmaceuticals LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.3.5 Aridis Pharmaceuticals LLC Recent Development
11.4 AstraZeneca Plc
11.4.1 AstraZeneca Plc Company Details
11.4.2 AstraZeneca Plc Business Overview
11.4.3 AstraZeneca Plc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.4.4 AstraZeneca Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.4.5 AstraZeneca Plc Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Details
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.5.4 Bayer AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.5.5 Bayer AG Recent Development
11.6 Cardeas Pharma Corp
11.6.1 Cardeas Pharma Corp Company Details
11.6.2 Cardeas Pharma Corp Business Overview
11.6.3 Cardeas Pharma Corp Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.6.4 Cardeas Pharma Corp Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.6.5 Cardeas Pharma Corp Recent Development
11.7 Destiny Pharma Ltd
11.7.1 Destiny Pharma Ltd Company Details
11.7.2 Destiny Pharma Ltd Business Overview
11.7.3 Destiny Pharma Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.7.4 Destiny Pharma Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.7.5 Destiny Pharma Ltd Recent Development
11.8 Dong-A Socio Holdings Co Ltd
11.8.1 Dong-A Socio Holdings Co Ltd Company Details
11.8.2 Dong-A Socio Holdings Co Ltd Business Overview
11.8.3 Dong-A Socio Holdings Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.8.4 Dong-A Socio Holdings Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.8.5 Dong-A Socio Holdings Co Ltd Recent Development
11.9 Lakewood-Amedex Inc
11.9.1 Lakewood-Amedex Inc Company Details
11.9.2 Lakewood-Amedex Inc Business Overview
11.9.3 Lakewood-Amedex Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.9.4 Lakewood-Amedex Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.9.5 Lakewood-Amedex Inc Recent Development
11.10 MedImmune LLC
11.10.1 MedImmune LLC Company Details
11.10.2 MedImmune LLC Business Overview
11.10.3 MedImmune LLC Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.10.4 MedImmune LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.10.5 MedImmune LLC Recent Development
11.11 Meiji Seika Pharma Co Ltd
11.11.1 Meiji Seika Pharma Co Ltd Company Details
11.11.2 Meiji Seika Pharma Co Ltd Business Overview
11.11.3 Meiji Seika Pharma Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.11.4 Meiji Seika Pharma Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.11.5 Meiji Seika Pharma Co Ltd Recent Development
11.12 Merck & Co Inc
11.12.1 Merck & Co Inc Company Details
11.12.2 Merck & Co Inc Business Overview
11.12.3 Merck & Co Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.12.4 Merck & Co Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.12.5 Merck & Co Inc Recent Development
11.13 Motif Bio Plc
11.13.1 Motif Bio Plc Company Details
11.13.2 Motif Bio Plc Business Overview
11.13.3 Motif Bio Plc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.13.4 Motif Bio Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.13.5 Motif Bio Plc Recent Development
11.14 Nabriva Therapeutics AG
11.14.1 Nabriva Therapeutics AG Company Details
11.14.2 Nabriva Therapeutics AG Business Overview
11.14.3 Nabriva Therapeutics AG Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.14.4 Nabriva Therapeutics AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.14.5 Nabriva Therapeutics AG Recent Development
11.15 Polyphor Ltd
11.15.1 Polyphor Ltd Company Details
11.15.2 Polyphor Ltd Business Overview
11.15.3 Polyphor Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.15.4 Polyphor Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.15.5 Polyphor Ltd Recent Development
11.16 Shionogi & Co Ltd
11.16.1 Shionogi & Co Ltd Company Details
11.16.2 Shionogi & Co Ltd Business Overview
11.16.3 Shionogi & Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.16.4 Shionogi & Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.16.5 Shionogi & Co Ltd Recent Development
11.17 Tetraphase Pharmaceuticals Inc
11.17.1 Tetraphase Pharmaceuticals Inc Company Details
11.17.2 Tetraphase Pharmaceuticals Inc Business Overview
11.17.3 Tetraphase Pharmaceuticals Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.17.4 Tetraphase Pharmaceuticals Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.17.5 Tetraphase Pharmaceuticals Inc Recent Development
11.18 The Medicines Company
11.18.1 The Medicines Company Company Details
11.18.2 The Medicines Company Business Overview
11.18.3 The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.18.4 The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.18.5 The Medicines Company Recent Development
11.18 Theravance Biopharma Inc
.1 Theravance Biopharma Inc Company Details
.2 Theravance Biopharma Inc Business Overview
.3 Theravance Biopharma Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
.4 Theravance Biopharma Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
.5 Theravance Biopharma Inc Recent Development
11.20 Wockhardt Ltd
11.20.1 Wockhardt Ltd Company Details
11.20.2 Wockhardt Ltd Business Overview
11.20.3 Wockhardt Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.20.4 Wockhardt Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.20.5 Wockhardt Ltd Recent Development
11.21 Zavante Therapeutics Inc
11.21.1 Zavante Therapeutics Inc Company Details
11.21.2 Zavante Therapeutics Inc Business Overview
11.21.3 Zavante Therapeutics Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.21.4 Zavante Therapeutics Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.21.5 Zavante Therapeutics Inc Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Prevention
Table 3. Key Players of Physiotherapy
Table 4. Key Players of Immunity Therapy
Table 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions (2022-2027)
Table 11. Ventilator Associated Pneumonia (VAP) Therapeutics Market Trends
Table 12. Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers
Table 13. Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges
Table 14. Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints
Table 15. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2020)
Table 18. Ranking of Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
Table 22. Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. Achaogen Inc Company Details
Table 63. Achaogen Inc Business Overview
Table 64. Achaogen Inc Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 65. Achaogen Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 66. Achaogen Inc Recent Development
Table 67. Adenium Biotech ApS Company Details
Table 68. Adenium Biotech ApS Business Overview
Table 69. Adenium Biotech ApS Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 70. Adenium Biotech ApS Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Adenium Biotech ApS Recent Development
Table 72. Aridis Pharmaceuticals LLC Company Details
Table 73. Aridis Pharmaceuticals LLC Business Overview
Table 74. Aridis Pharmaceuticals LLC Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 75. Aridis Pharmaceuticals LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Aridis Pharmaceuticals LLC Recent Development
Table 77. AstraZeneca Plc Company Details
Table 78. AstraZeneca Plc Business Overview
Table 79. AstraZeneca Plc Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 80. AstraZeneca Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 81. AstraZeneca Plc Recent Development
Table 82. Bayer AG Company Details
Table 83. Bayer AG Business Overview
Table 84. Bayer AG Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 85. Bayer AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 86. Bayer AG Recent Development
Table 87. Cardeas Pharma Corp Company Details
Table 88. Cardeas Pharma Corp Business Overview
Table 89. Cardeas Pharma Corp Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 90. Cardeas Pharma Corp Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 91. Cardeas Pharma Corp Recent Development
Table 92. Destiny Pharma Ltd Company Details
Table 93. Destiny Pharma Ltd Business Overview
Table 94. Destiny Pharma Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 95. Destiny Pharma Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 96. Destiny Pharma Ltd Recent Development
Table 97. Dong-A Socio Holdings Co Ltd Company Details
Table 98. Dong-A Socio Holdings Co Ltd Business Overview
Table 99. Dong-A Socio Holdings Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Dong-A Socio Holdings Co Ltd Recent Development
Table 101. Lakewood-Amedex Inc Company Details
Table 102. Lakewood-Amedex Inc Business Overview
Table 103. Lakewood-Amedex Inc Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 104. Lakewood-Amedex Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 105. Lakewood-Amedex Inc Recent Development
Table 106. MedImmune LLC Company Details
Table 107. MedImmune LLC Business Overview
Table 108. MedImmune LLC Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 109. MedImmune LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 110. MedImmune LLC Recent Development
Table 111. Meiji Seika Pharma Co Ltd Company Details
Table 112. Meiji Seika Pharma Co Ltd Business Overview
Table 113. Meiji Seika Pharma Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 114. Meiji Seika Pharma Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 115. Meiji Seika Pharma Co Ltd Recent Development
Table 116. Merck & Co Inc Company Details
Table 117. Merck & Co Inc Business Overview
Table 118. Merck & Co Inc Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 119. Merck & Co Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 120. Merck & Co Inc Recent Development
Table 121. Motif Bio Plc Company Details
Table 122. Motif Bio Plc Business Overview
Table 123. Motif Bio Plc Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 124. Motif Bio Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 125. Motif Bio Plc Recent Development
Table 126. Nabriva Therapeutics AG Company Details
Table 127. Nabriva Therapeutics AG Business Overview
Table 128. Nabriva Therapeutics AG Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 129. Nabriva Therapeutics AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 130. Nabriva Therapeutics AG Recent Development
Table 131. Polyphor Ltd Company Details
Table 132. Polyphor Ltd Business Overview
Table 133. Polyphor Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 134. Polyphor Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 135. Polyphor Ltd Recent Development
Table 136. Shionogi & Co Ltd Company Details
Table 137. Shionogi & Co Ltd Business Overview
Table 138. Shionogi & Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 139. Shionogi & Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 140. Shionogi & Co Ltd Recent Development
Table 141. Tetraphase Pharmaceuticals Inc Company Details
Table 142. Tetraphase Pharmaceuticals Inc Business Overview
Table 143. Tetraphase Pharmaceuticals Inc Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 144. Tetraphase Pharmaceuticals Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 145. Tetraphase Pharmaceuticals Inc Recent Development
Table 146. The Medicines Company Company Details
Table 147. The Medicines Company Business Overview
Table 148. The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 149. The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 150. The Medicines Company Recent Development
Table 151. Theravance Biopharma Inc Company Details
Table 152. Theravance Biopharma Inc Business Overview
Table 153. Theravance Biopharma Inc Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 154. Theravance Biopharma Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 155. Theravance Biopharma Inc Recent Development
Table 156. Wockhardt Ltd Company Details
Table 157. Wockhardt Ltd Business Overview
Table 158. Wockhardt Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 159. Wockhardt Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 160. Wockhardt Ltd Recent Development
Table 161. Zavante Therapeutics Inc Company Details
Table 162. Zavante Therapeutics Inc Business Overview
Table 163. Zavante Therapeutics Inc Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 164. Zavante Therapeutics Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 165. Zavante Therapeutics Inc Recent Development
Table 166. Research Programs/Design for This Report
Table 167. Key Data Information from Secondary Sources
Table 168. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Prevention Features
Figure 3. Physiotherapy Features
Figure 4. Immunity Therapy Features
Figure 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Ambulatory Surgical Center Case Studies
Figure 8. Diagnostic Centers Case Studies
Figure 9. Ventilator Associated Pneumonia (VAP) Therapeutics Report Years Considered
Figure 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions: 2020 VS 2027
Figure 13. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions (2022-2027)
Figure 14. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players in 2020
Figure 15. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2020
Figure 17. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2016-2021)
Figure 18. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2022-2027)
Figure 19. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2016-2027)
Figure 21. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2016-2027)
Figure 22. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2016-2027)
Figure 23. United States Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2016-2027)
Figure 27. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2016-2027)
Figure 28. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2016-2027)
Figure 29. Germany Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2016-2027)
Figure 39. China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2016-2027)
Figure 47. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2016-2027)
Figure 48. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2016-2027)
Figure 49. Mexico Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2016-2027)
Figure 55. Turkey Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Achaogen Inc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 59. Adenium Biotech ApS Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 60. Aridis Pharmaceuticals LLC Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 61. AstraZeneca Plc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 62. Bayer AG Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 63. Cardeas Pharma Corp Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 64. Destiny Pharma Ltd Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 65. Dong-A Socio Holdings Co Ltd Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 66. Lakewood-Amedex Inc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 67. MedImmune LLC Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 68. Meiji Seika Pharma Co Ltd Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 69. Merck & Co Inc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 70. Motif Bio Plc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 71. Nabriva Therapeutics AG Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 72. Polyphor Ltd Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 73. Shionogi & Co Ltd Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 74. Tetraphase Pharmaceuticals Inc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 75. The Medicines Company Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 76. Theravance Biopharma Inc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 77. Wockhardt Ltd Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 78. Zavante Therapeutics Inc Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed